Investing in the Weight Loss Sector
The weight loss industry is booming, and many investors are eyeing stocks like Eli Lilly and Novo Nordisk, thanks to their solid market presence and promising products. While these companies are valued at over $500 billion, which seems appealing, their high valuation might limit future growth compared to some lesser-known options.
Amgen: A Potential Powerhouse in Weight Loss
A stock that stands out as a potential investment is Amgen (NASDAQ: AMGN). With a market cap below $200 billion, it offers an intriguing alternative that could experience significant growth as it solidifies its position in the glucagon-like peptide-1 (GLP-1) market.
Revolutionary Drug Potential
Amgen is working on a drug named MariTide, which may only need to be administered once a month—or even less frequently—unlike current products like Zepbound and Wegovy from Eli Lilly and Novo Nordisk, which typically require weekly doses. This weekly commitment can make it hard for patients to stick with the treatment long term. Early trial results suggest that MariTide could lead to weight loss of around 15% after just 12 weeks, without significant weight regain, making it an exciting development for both patients and investors.
The Strength of Amgen’s Operations
Beyond its upcoming foray into the GLP-1 market, Amgen has a diverse and solid portfolio. The company is actively expanding its capabilities through strategic acquisitions, such as acquiring ChemoCentryx and recently Horizon Therapeutics, which adds the promising Tepezza treatment for thyroid eye disease. This could potentially generate up to $4 billion in peak annual revenue.
Impressive Financial Performance
In its latest financial report, Amgen achieved an impressive $8.4 billion in sales, reflecting a remarkable 20% increase from the previous year. Several high-growth products, including Repatha, contributed to this success, with Repatha alone generating $532 million—a year-over-year growth rate of 25%. Given Amgen's extensive product lineup and innovative pipeline, it is considered a solid growth investment option for those looking to invest long term.
Assessing Amgen as an Investment
Even though shares of Eli Lilly and Novo Nordisk have risen by over 25% this year, Amgen's stock has only grown by a modest 11%. This slower growth has led to reduced enthusiasm in the market about Amgen's potential, especially if MariTide secures regulatory approval. Nevertheless, investing in Amgen still appears to be a calculated risk worth considering due to its overall business strategy and comparatively low trading valuation, which stands at just 16 times its expected future earnings.
Conclusion: Is Amgen a Worthy Investment?
Before deciding on an investment, it's crucial to consider Amgen's current standing and potential future in the market. While some analysts haven't put Amgen on their top stock picks list, its unique products and strong financial position make a strong argument for investors. As competition grows in the healthcare sector, stocks like Amgen might present valuable opportunities for those wanting to tap into the weight loss sector's growth.
Frequently Asked Questions
What is Amgen known for?
Amgen is a prominent biotechnology company recognized for creating innovative therapies, especially in oncology and weight loss with drugs like MariTide.
How does MariTide differ from existing weight loss drugs?
Unlike many current weight loss treatments that require weekly injections, MariTide may be given monthly or even less often, which could help improve patient adherence.
What are Amgen's recent financial highlights?
In its last quarter, Amgen reported $8.4 billion in sales, marking a 20% increase compared to the previous year, largely driven by several successful products like Repatha.
Is investing in Amgen a safe choice?
Investing in Amgen is considered a calculated risk, particularly due to its diverse product portfolio and innovative potential, even though its market valuation is currently lower than that of its competitors.
What factors could influence Amgen's stock price?
Factors like the approval of MariTide and steady growth in its current product lines will significantly impact Amgen's stock price moving forward.
